Intermittent doxercalciferol (1α-Hydroxyvitamin D2) therapy for secondary hyperparathyroidism

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study

GA Block, TE Hulbert-Shearon, Levin Nw et al. · American Journal of Kidney Diseases · 1998 · 2.4K citations

Medicine, Nephrology, Dialysis +16

Hypovitaminosis D in Medical Inpatients

Melissa K. Thomas, Donald M. Lloyd‐Jones, Ravi Thadhani et al. · New England Journal of Medicine · 1998 · 1.4K citations · Full text

Medicine, Internal Medicine, Clinical Medicine +7

The spectrum of bone disease in end-stage renal failure—An evolving disorder

Donald J. Sherrard, Gavril Hercz, York Pei et al. · Kidney International · 1993 · 737 citations

Medicine, Nephrology, Bone Metabolism +15

Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.

Eduardo Slatopolsky, Carol Weerts, J Thielan et al. · Journal of Clinical Investigation · 1984 · 686 citations · Full text

Medicine, Endocrinology, Pharmacology +15

Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.

Nobuto Fukuda, Hideaki Tanaka, Yohei Tominaga et al. · Journal of Clinical Investigation · 1993 · 599 citations · Full text

Medicine, Endocrinology, Nephrology +11